ERBB2 and breast cancer: As expected, the ErbB2 expression detected in 14.4% (42/292) of patients (26 missing values) was significantly associated with BrM (p = 0.003): 24.7% (19/77) of breast cancers that progressed to brain metastasis were positive versus 12.8% (6/47) and 10.1% (17/168) of breast carcinomas that relapsed in other locations (such as lung, liver, bone or non-regional lymph nodes) or without metastasis, respectively.